Evidence map›Paper›PMID 16907977›Full record

ArticleParticle and fibre toxicology2006

The potential risks of nanomaterials: a review carried out for ECETOC.

Paul J A Borm, David Robbins, Stephan Haubold, Thomas Kuhlbusch, Heinz Fissan, Ken Donaldson, Roel Schins, Vicki Stone, Wolfgang Kreyling, Jurgen Lademann and 3 more

Open access · goldAbstract read
In one paragraph

Article in Particle and fibre toxicology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 1 pooled it
48.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,325 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Mg(OH)ChemistryOpen · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Understanding the toxicological effects of TiOParticle and fibre toxicology · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Remediation of Metal Oxide Nanotoxicity with a Functional Amyloid.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Review

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 4 countries.

Paul J A BormCentre of Expertise in Life Sciences, Zuyd University, Heerlen, The Netherlands.
David Robbins
Stephan Haubold
Thomas Kuhlbusch
Heinz Fissan
Ken Donaldson
Roel Schins
Vicki Stone
Wolfgang Kreyling
Jurgen Lademann
Jean Krutmann
David Warheit
Eva Oberdorster
Heinrich Heine University Düsseldorf · DEInstitut für Energie- und Umwelttechnik · DECharité - Universitätsmedizin Berlin · DEDuPont (United States) · USEdinburgh Napier University · GBInstitute of Groundwater Ecology · DENanogate (Germany) · DESouthern Methodist University · USUniversity of Edinburgh · GBZuyd University of Applied Sciences · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the last few years, research on toxicologically relevant properties of engineered nanoparticles has increased tremendously. A number of international research projects and additional activities are ongoing in the EU and the US, nourishing the expectation that more relevant technical and toxicological data will be published. Their widespread use allows for potential exposure to engineered nanoparticles during the whole lifecycle of a variety of products. When looking at possible exposure routes for manufactured Nanoparticles, inhalation, dermal and oral exposure are the most obvious, depending on the type of product in which Nanoparticles are used. This review shows that (1) Nanoparticles can deposit in the respiratory tract after inhalation. For a number of nanoparticles, oxidative stress-related inflammatory reactions have been observed. Tumour-related effects have only been observed in rats, and might be related to overload conditions. There are also a few reports that indicate uptake of nanoparticles in the brain via the olfactory epithelium. Nanoparticle translocation into the systemic circulation may occur after inhalation but conflicting evidence is present on the extent of translocation. These findings urge the need for additional studies to further elucidate these findings and to characterize the physiological impact. (2) There is currently little evidence from skin penetration studies that dermal applications of metal oxide nanoparticles used in sunscreens lead to systemic exposure. However, the question has been raised whether the usual testing with healthy, intact skin will be sufficient. (3) Uptake of nanoparticles in the gastrointestinal tract after oral uptake is a known phenomenon, of which use is intentionally made in the design of food and pharmacological components. Finally, this review indicates that only few specific nanoparticles have been investigated in a limited number of test systems and extrapolation of this data to other materials is not possible. Air pollution studies have generated indirect evidence for the role of combustion derived nanoparticles (CDNP) in driving adverse health effects in susceptible groups. Experimental studies with some bulk nanoparticles (carbon black, titanium dioxide, iron oxides) that have been used for decades suggest various adverse effects. However, engineered nanomaterials with new chemical and physical properties are being produced constantly and the toxicity of these is unknown. Therefore, despite the existing database on nanoparticles, no blanket statements about human toxicity can be given at this time. In addition, limited ecotoxicological data for nanomaterials precludes a systematic assessment of the impact of Nanoparticles on ecosystems.

Identifiers

PMID16907977
PMCPMC1584248
OpenAlexW2130538711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.